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Background: Apigenin is a nontoxic dietary flavonoid, and it may have chemopreventive and therapeutic potential
as an anti-inflammatory, antioxidant, and anti-cancer agent. However, its role in bladder cancer remains poorly
understood. The aim of this study was to investigate the anti-proliferative activity of apigenin in human bladder
cancer T-24 cells.
Methods and results: Apigenin inhibited T-24 cell proliferation in a dose-dependent manner. We demonstrated
that apigenin-induced early and mid-apoptotic cell could be identified by Annexnin V-Alexa Fluor 488/PI apoptosis
detection and TUNEL assay. Moreover, using a JC-1 staining assay, we found that apigenin may induce the loss of
the mitochondrial membrane potential. By performing flow cytometry and Western blotting, apigenin-mediated
subG1 phase acculmulation was also associated with an increase in the phospho-p53, p53, p21, and p27 levels, and
with a decrease in the Cyclin A, Cyclin B1, Cyclin E, CDK2, Cdc2, and Cdc25C levels, thereby blocking cell cycle
progression. ELISA showed that the subG1 phase acculmulation was due to the increase in the p53, p21, and
p27 levels. In addition, apigenin increased the Bax, Bad, and Bak levels, but reduced the Bcl-xL, Bcl-2, and Mcl-1
levels, and subsequently triggered the mitochondrial apoptotic pathway (release of cytochrome c and activation
of caspase-9, caspase-3, caspase-7, and PARP). Further analysis demonstrated that apigenin increased the ROS
levels and depleted GSH in T-24 cells at 12 h.
Conclusions: The results suggested that apigenin inhibits T-24 cells proliferation via blocking cell cycle progression
and inducing apoptosis. In addition, we discovered a potential anticancer activity of apigenin against T-24 cells.
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Bladder cancer ranks the second most common malignancy
of the genitourinary tract and is associated with significant
morbidity and mortality [1]. Although most bladder cancer
cases are superficial at the time of diagnosis, including sur-
gery, intravesical chemotherapy, radiation/immunotherapy
therapy, and system chemotherapy. However, bladder cancer
is associated with a poor prognosis, because it is highly
resistant to radiation and chemotherapeutic agents. In* Correspondence: shih723@seed.net.tw
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unless otherwise stated.addition, patients with advanced bladder cancer have a
5-year survival rate of approximately 20-40% despite
various treatment modalities [2-4]. Therefore, novel
and effective therapeutic strategies for the treatment of
advanced bladder cancer are urgently required. Human
urinary bladder tumours are known to develop along 2
major and independent biological axes, each presenting
with diverse and discrete genetic alterations controlling
tumour initiation and progression [5,6]. The complexity of
the molecular pathways involved in bladder cancer onset,
combined with the various genetic and epigenetic events
occurring during tumour progression, are mainly respon-
sible for the profound heterogeneity of this disease [7,8].
Apoptosis plays a major role in the homeostasis and
development of tissues in multicellular organisms [9].
Biochemical events lead to cell morphology changes ands is an Open Access article distributed under the terms of the Creative
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totic cell death results in critical diseases such as cancer
[9,10]. In many cell models, the mode of death produced
by an initiation stimulus may be switched by inhibiting
control points or major execution steps in the death
pathway, such as caspase activation, cytochrome c release,
or reactive oxygen species (ROS) generation [11-13].
In recent years, scientific interest in mitochondria
which plays a vital role in cell death processes. Several
stressors, such as inflammation, radiation (ultraviolet
or X-rays), heavy metals, drugs, heat shock, and acidifi-
cation, are inducers of apoptosis, and they are involved
in the opening of the permeability transition pore, in-
crease of the Bax/Bcl-2 ratio, and generation of ROS
from mitochondria, which may cause the release of
apoptogenic factors [14]. Furthermore, intracellular re-
duced glutathione (GSH) content has a decisive effect
on anticancer drug-induced apoptosis, indicating that
apoptotic effects are inversely proportional to GSH
content [15,16].
Multiple genetic changes occurring during carcinogen-
esis cause cell abnormalities. Recent advances in cell
biology have illustrated the detailed mechanisms of the
cell-cycle regulatory systems and have shown that increased
cell proliferation is a common characteristic in numerous
cancers [17,18]. Cell cycle progression involves a sequential
activation of CDKs, the activation of which is dependent on
the association with cyclins. Therefore, eukaryotic cells have
developed effective and well-regulated mechanisms to con-
trol cell-cycle progression [19].
Increased intake of fruits and vegetables has been
associated with reduced risks of certain cancers [20].
Apigenin (4′,5,7,-trihydroxyflavone) is a common dietary
flavonoid and is widely distributed in several fruits and
vegetables, such as parsley, onions, oranges, and tea [21].
Naturally occurring apigenin is found mostly in hydroxyl-
ated form, and has been demonstrated to inhibit tumour
cell proliferation, motility, angiogenesis, and induce apop-
tosis [22-25]. Although various studies have shown that
apigenin possesses antitumour properties, the mecha-
nisms underlying its antitumour activity remain unknown.
In this study, we have employed the human bladder
cancer T-24 cell line to understand the molecular
mechanisms responsible for the antiproliferative effect
of apigenin. We demonstrated that apigenin inhibited
T-24 cells proliferation via blocking cell cycle progres-
sion and inducing apoptosis.
Material and methods
Reagents and antibodies
Apigenin (purity≧99%) was purchased from Extrasynthese
(Genay, France); dimethylsulfoxide (DMSO), sodium
dodecyl sulphate (SDS), phenylmethylsulfonyl fluoride,
and bovine serum albumin (BSA) were purchased fromSigma-Aldrich Chemical Co. (St. Louis, MO, USA); the
Annexin V-Alexa Fluor 488 and propidium iodide (PI)
apoptosis detection kit were purchased from Invitrogen
(Molecular Probe, Inc, Eugene, OR, USA). The protein assay
kit was obtained from Bio-Rad Labs. (Hercules, CA, USA).
Dulbecco’s phosphate-buffer saline (PBS), and trypsin-
EDTA were purchased from Gibco-BRL (Gaithersburg,
MD, USA). Mouse- or rabbit-monoclonal antibodies spe-
cific for cytochrome c, caspase-3, caspase-7, caspase-9,
Cyclin B1, Cyclin E, and CDK2 were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Mouse- or rabbit-monoclonal antibodies specific for
phospho-p53, p53, p21, p27, Bcl-2, Bcl-xL, Mcl-1, Bax,
Bad, Bak, poly( ADP-ribose) polymerase (PARP), Cdc2,
Cdc25C, and Cyclin A were purchased from Invitrogen
Corporation (Camarillo, CA, USA). β-Actin antibody
was purchased from BD Transduction Laboratories
(San Diego, CA, USA). The enhanced chemiluminescence
(ECL) kit was purchased from Amersham Life Science
(Amersham, UK).
Cell culture and apigenin treatment
Human nonmalignant lung fibroblast cell line WI-38
and bladder carcinoma cell line HT-1376 were main-
tained in MEM medium. Human bladder carcinoma cell
line T-24 was maintained in MacCoy’s 5A medium. Hu-
man prostate carcinoma cell line PC-3 was maintained
in Ham’s F12K medium. The aforementioned cell lines
were obtained from BCRC (Bioresource Collection and
Research Center, Hsin-Chu, Taiwan). All cells were
cultured at 37°C in a humidified atmosphere of 5%
CO2-95% air. In medium supplemented with 10% fetal
calf serum and antibiotics (100 U/ml of penicillin and
100 mg/ml of streptomycin). Adherent cells were detached
by incubation with trypsin. For apigenin treatment, the
stock solution of apigenin was dissolved in DMSO
and sterilised by filtration through 0.2-μm disc filters.
Appropriate amounts of the stock solution (1 mg/ml
in DMSO) of apigenin were added to the culture
medium to achieve the indicated concentrations (final
DMSO concentration was < 0.2%).
Cell viability
To measure the effect of apigenin on cell viability, the
WI-38, T-24, HT-1376 and PC-3 cells were seeded in
24-well plates (1 × 105 cells/well) for 16–18 h. The cells
were then treated with or without various concentrations
(0, 1, 5, 10, 20, 30, 40, and 50 μg/ml) of apigenin for 24 h.
Each treatment was repeated 3 times. After the expos-
ure period, the medium was removed and followed by
washing the cells with PBS. The medium was then
changed and incubated with 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) solution
(5 mg/ml)/well for 4 h. The medium was removed,
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sured spectrophotometrically at 563 nm. The percentage
of viable cells was estimated by comparing them with the
untreated control cells.
Cell-cycle assay
Flow cytometric analysis of T-24 cells was performed
using a FACScan flow cytometer (Becton Dickinson
Immunocytometry Systems, UK). To analyse cell cycle
distribution, the cells were initially treated with various
concentrations (0, 1, 5, 10, 20, 30, and 40 μg/ml) of
apigenin for 24 h, and were then collected by trypsini-
sation, fixed in 75% absolute ethanol, washed in PBS,
and resuspended in 1 ml of PBS containing 0.5 mg/ml
of RNase A and 0.01 mg/ml of PI in the dark for
30 min at room temperature. The cell cycle profiles
were analysed using by a flow cytometer. The percent-
age of cells in the sub-G1, G0/G1, S, and G2/M phases
of the cell cycle was analysed using the ModFit LT 3.0
software (Verity Software, Topsham, ME, USA).
Annexin V-Alexa fluor 488 and PI apoptosis detection
assay
Quantitative assessment of apoptosis was performed
using the Annexin V-Alexa Flour 488 and PI apoptosis
detection kit. Briefly, cells were seeded in 6-well plates,
grown for 16–18 h, and treated with apigenin (0, 20, and
30 μg/ml) for the indicated times. After the exposure
period, the medium was removed, and the cells were
washed with Ca2+/Mg2+- free PBS. The cells were then
fixed with 4% paraformaldehyde in Ca2+/Mg2+-free PBS
for 15 min. In addition, the cells were subsequently washed
with annexin-binding buffer [20 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), 700 mM NaCl,
12.5 mM CaCl2, pH 7.4] and stained with Annexin V-Alexa
Fluor 488 and PI for 15 min in the dark at room
temperature. We then observed the cells under a fluores-
cence microscope by using a dual filter set for fluorescein
isothiocyanate (FITC) and rhodamine (BX51, Olympus,
Tokyo, Japan). Apoptotic cells were defined as Annexin
V-Alexa Fluor 488-positive and PI-negative cells. Our
definition of cellular status is as follows: unstained
cells were classified as ‘live’, cells stained for Annexin
V-Alexa Fluor 488 only were ‘early apoptotic’, cells
stained for both Annexin V-Alexa Fluor 488 and PI
were ‘late apoptotic’, and cells stained for PI only were
‘dead’. Apoptotic cells were the sum of early and late
apoptotic cells.
TUNEL assay
We applied a quantitative evaluation method by perform-
ing terminal deoxynucleotidyl transferase-mediated deox-
yuridine triphosphate nick-end labelling (TUNEL) method
to examine DNA strand breaks during apoptosis. In brief,cells were seeded in 6-well plates, and were treated
with various concentrations (0, 5, 10, 20, 30, and 40 μg/ml)
of apigenin for 6 h. After the exposure period, the medium
was removed, and the cells were then washed with
Ca2+/Mg2+- free PBS. Cells were fixed with 4% parafor-
maldehyde and permeabilised with 0.1% Triton X-100 in
0.1% sodium citrate. After washing, the cells were incu-
bated with the reaction mixture provided in the APO-
BrdUTM TUNEL Assay kit (Molecular Probe, Inc). The
apoptotic cells with fragmented chromosomal DNA ends
were labelled with TdT, which exhibited bead-like green
fluorescence under a fluorescence microscope at 20×
magnification.
Mitochondrial-membrane potential assay
We used the mitochondrial-specific cationic dye JC-1
(5,5′,6,6′-tetrachloro-1,1′,3,3′- tetraethyl-benzimidazolyl
carbocyanine iodide) (Molecular Probe, Inc), which
undergoes potential-dependent accumulation in the
mitochondria. JC-1 is selectively accumulated within
intact mitochondria to form multimer J-aggregates emitting
fluorescence light at 590 nm (red) at a higher membrane
potential, and monomeric JC-1 emits fluorescence light
at 527 nm (green) at a low membrane potential. The
cells were seeded in 6-well plates, and were treated
with 0–30 μg/ml of apigenin for 3 and 24 h. After the
exposure period, the medium was removed, and the
cells were washed with Ca2+/Mg2+-free PBS. The cells
were then stained with 10 μg/ml of JC-1 for 30 min at
37°C and were examined under a fluorescence microscope.
Thus, the fluorescence signals were detected by the colour
of emitted light by JC-1 indicate the mitochondria mem-
brane potential, which can be analysed by a fluorescence
microscope equipped with a dual band-pass filter (detects
FITC and rhodamine). Based on the results, we categorised
the cells as healthy cells and apoptotic cells. In healthy
cells, the dye accumulates and aggregates in the mitochon-
dria, emitting a bright red fluorescence. In apoptotic cells,
the dye cannot aggregate in the mitochondria because of
the altered mitochondrial membrane potential, and thus it
remains in the cytoplasm (monomeric form) and emits a
green fluorescence.
Preparation of whole-cell lysates and Western blotting
assay
The cells were lysed with iced-cold radioimmunoprecipi-
tation assay (RIPA) buffer (1% NP-40, 50 mM Tris Base,
0.1% SDS, 0.5% deoxycholic acid, 150 mM NaCl, pH 7.5)
and then phenylmethylsulfonyl fluoride (10 mg/ml), leu-
peptin (17 mg/ml), and sodium orthovanadate (10 mg/ml)
were added. After vortexing on ice for 30 min, the samples
were centrifuged at 12000 × g for 10 min, and then the su-
pernatants were collected, denatured, and subjected to so-
dium dodecyl sulphate-polyacrylamide gel electrophoresis
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was determined using a Bio-Rad protein assay reagent
with BSA as a standard. We performed ECL Western blot-
ting was as follows. Proteins were resolved on 10-12%
SDS-PAGE gels and then transferred onto nitrocellulose
membranes. Nonspecific binding of the membranes was
blocked with Tris-buffered saline (TBS) containing 1% (w/v)
nonfat dry milk and 0.1% (v/v) Tween-20 (TBST) for more
than 2 h. The membranes were washed with TBST 3 times
for 10 min and incubated with an appropriate dilution
of specific primary antibodies in TBST overnight at 4°C.
Subsequently, the membranes were washed with TBST
and incubated with an appropriate secondary antibody
(horseradish peroxidase-conjugated goat antimouse or
antirabbit IgG) for 1 h. After the membranes were
washed 3 times for 10 min in TBST, the bands were
detected through enhanced chemiluminescence by using
ECL Western blotting detection reagents and exposed
ECL hyperfilm in FUJIFILM Las-3000 mini-imaging sys-
tem (Tokyo, Japan). Proteins were then quantitatively de-
termined through densitometry by using FUJIFILM-Multi
Gauge V3.0 software.
Measuring of p53, p21, and p27 levels
Intracellular levels of the levels of p53, p21, and p27 were de-
termined by enzyme-linked immunosorbent assay (ELISA).
In brief, T-24 cells were seeded in 5-cm dishes and grown to
85-90% confluence, and were then treated with 0, 20, and
30 μg/ml of apigenin for 6, 12, 24, and 48 h. Cell lysates were
placed in 96-well microtiter plates (1 × 106 per well) coated
with monoclonal detective antibodies, and then incubated
for 2 h at room temperature. After the unbound antibodies
were removed through washing with a washing buffer
(50 mM Tris, 200 mM NaCl, and 0.2% Tween 20), the
detection antibody, which is bound by horseradish
peroxidase-conjugated streptavidin, was added to bind to
the antibodies. Horseradish peroxidase catalysed the con-
version of a chromogenic substrate (tetramethylbenzidine)
to a coloured solution with colour intensity propor-
tional to the protein level present in the sample. The
absorbance of each well was measured at 450 nm, and
p53, p21, and p27 levels were determined by interpol-
ating from standard curves obtained with known levels
of standard proteins. Data are expressed as pg p53,
p21, or p27 levels (pg/106 cells).
Measurement of intracellular levels of ROS
Intracellular ROS was estimated using a fluorescent
probe, 2′,7′-dichlorofluorescein diacetate (DCFH-DA).
DCFH-DA readily diffuses through the cell membrane
and is enzymatically hydrolysed by intracellular esterases
to non-fluorescent dichlorofluorescin (DCFH), which is
then rapidly oxidised to highly fluorescent DCF in the
presence of ROS. Briefly, the cells were treated with30 μg/ml of apigenin for various periods (0, 1, 2, 3, 6,
and 12 h). T-24 cells (1 × 105 cells/ml) were then incu-
bated in a culture medium containing 20 μM DCFH-DA
for 30 min at 37°C, and were washed with PBS. The cell
suspensions were centrifuged at 412 × g for 10 min and
the medium was removed. Cells were dissolved with 1%
Triton X-100, and DCF fluorescence intensity was de-
tected at various time intervals with an excitation wave-
length of 503 nm and an emission wavelength of 529 nm
by using the FLUOstar OPTIMA spectrofluorophot-
ometer. DCF fluorescence intensity is proportional to
the intracellular ROS levels [26].
Measurement of intracellular levels of GSH
The intracellular levels of GSH were measured using the
method of Hissin and Hilf [27]. After treatment, cells were
washed with PBS and scrapped into 6.5% trichloroacetic
acid. Phosphate-EDTA buffer (4.5 ml) at pH 8.0 was
added to 0.5 ml of the supernatant obtained after cen-
trifugation at 12000 × g. The final assay mixture (2 ml)
contained 100 μl of diluted supernatant, 1.8 ml of
phosphate-EDTA buffer (pH 8.0), and 100 μl of 0.1%
o-phthalaldehyde solution. After thorough mixing and
incubation at room temperature for 15 min, fluores-
cence was read at wavelengths of 350 nm (excitation)
and 420 nm (emission) using the FLUOstar OPTIMA
spectrofluorophotometer. The reduced form of GSH
was used as a standard. Data are expressed as nano-
mole GSH per 106 cells.
Statistical analysis
Data are expressed as means ± standard deviation of 3 in-
dependent experiments and analysed using Student’s t-test
(Sigmaplot 2001, SPSS Inc., Chicago, IL, USA). P values
of <0.05 were considered statistically significant.
Results
Apigenin inhibited T-24 cells proliferation
The chemical structure of apigenin is illustrated in Figure 1A.
To investigate the effect of apigenin on cell viability in the
four cell lines (WI-38, T-24, HT-1376 and PC-3), the cell
viability was determined using a MTT assay. The results
showed that apigenin reduced the viability of these three cell
lines, T-24, HT-1376, and PC-3 in a dose-dependent manner
(Figure 1B). Particularity, the IC50 values of apigenin were
23.6, 35.2, and 40.2 μg/ml for T-24, HT-1376, and PC-3 cells
at 24 h, respectively. Among these cells, T-24 cells were
much more sensitive to apigenin compared with the other
cell lines. Furthermore, the strongest potency of apigenin on
the cytotoxicity of cancerous cells was toward T-24 bladder
cancer cells; therefore, we selected the T-24 cell line for sub-
sequent experiments. Apigenin had no cytotoxic effect
towardsWI-38 cells (Figure 1C).
Figure 1 The effects of apigenin on the viability in four cell lines, WI-38, T-24, HT-1376 and PC-3 cells. (A) Chemical structure of apigenin.
(B) Three cultured cells (T-24, HT-1376, PC-3) and (C) WI-38 cells were treated with or without apigenin under various concentrations (0, 1, 5, 10,
20, 30, 40, and 50 μg/ml) for 24 h. Thereafter, cell viabilities were determined by MTT assay. The survival cell number was directly
proportional to formazan, which was measured spectrophotometrically at 563 nm. Values represent mean ± SD of three independent
experiments (*P < 0.05, **P < 0.01, ***P < 0.001 compared with the untreated control (dose 0).
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To test the underlying mechanism that leads to the
apigenin-induced loss of cell proliferation, we observed
the effects of apigenin on T-24 cells by detecting the
apoptotic effect and cell cycle progression. Briefly, T-24
cells were treated with 0, 1, 5, 10, 20, 30, and 40 μg/ml
of apigenin for 24 h and subjected to flow cytometry.
The cells were treated with apigenin (0–40 μg/ml) for
24 h, an apparent accumulation of cells in the sub-G1
phase (at the hypodiploid phase, also named subG1
phase) from 6.2% to 78.5% was observed (Figure 2A).
The subG1 phase increased (greater than 50%) when the
cells were treated with 20–40 μg/ml of apigenin. In
addition, apigenin treatment significantly reduced the
percentage of cells in the G2/M phase. No change in the
S phase was observed. Thus, these results showed that
apigenin inhibited T-24 cells proliferation.
Subsequently, we assessed the effects of apigenin on
the induction of apoptosis in T-24 cells by performing
Annexin V-Alexa Fluor 488/PI assay and TUNEL assays.
First, the Annexin V-Alexa Fluor 488/PI double-staining
technique was performed to investigate whether apigenin
induced early apoptosis in T-24 cells. The percentage of
T-24 cells undergoing early apoptotic cell death was in-
creased by apigenin in a dose- and time-dependentmanner (Figure 2B). To further confirm apigenin-induced
apoptosis, a TUNEL assay was performed to detect DNA-
strand breaks. The assay results revealed that exposure of
T-24 cells to 5–40 μg/ml of apigenin for 6 h, resulted in
an appreciable increase of fluorescein-stained nuclei com-
pared with untreated control cells (Figure 2C).
Apigenin-induced the loss of mitochondrial membrane
potential and the release of cytochrome c in T-24 cells
The loss of mitochondrial membrane potential is an early
event in apoptosis. Therefore, we assessed the effect of
apigenin treatment on the mitochondrial membrane
potential (△Ψm) by using a fluorescence microscope
and JC-1 fluorescent dye. As shown in Figure 3A,
When the T-24 cells were incubated with 0–40 μg/ml
of apigenin for 3 and 24 h, the intensity of red fluorescence
decreased, whereas that of green fluorescence increased in
the cytoplasm with an increase in the apigenin level.
Further indication of the loss of mitochondrial membrane
potential were more obvious in high-dose (20 and 30 μg/ml)
apigenin-treated cells, By contrast, when the T-24 cells were
treated with 5 and 10 μg/ml of apigenin for 3 and 24 h,
no change was observed in the mitochondrial mem-
brane potential (data not shown). Moreover, T-24 cells
were incubated with 20 and 30 μg/ml of apigenin for
24 h drastically reduced the mitochondrial membrane
Figure 2 Apigenin inhibited cell cycle progress and induced apoptosis in T24 cells. (A) Cultured cells were treated with or without
apigenin under various concentrations (0–40 μg/ml). Twenty-four hours later, the cell cycle distribution was analysed by flow cytometry. The data
indicate the percentage of cells in sub-G1, G0/G1, S, and G2/M phases of the cell cycle. (B) Cells were treated with apigenin (0, 20, and 30 μg/ml)
for the indicated times, and then the induction of apoptosis was assessed by Annexin V-Alexa Fluor 488/PI assay kit. (C) Cells were treated with
or without apigenin under various concentrations (0–40 μg/ml), and then the induction of apoptosis was assessed by TUNEL assay kit. The results
represented the average of three independent experiments ± S.D. *P < 0.05, **P < 0.01, ***P < 0.001 compared with the untreated control.
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Disruption of the mitochondrial membrane results in
the release of cytochrome c from the mitochondrial
into the cytosol; consequently, cytochrome c can be de-
tected by Western blotting. Our results revealed that
apigenin treatment of T-24 cells led to the release of
cytochrome c from the mitochondria in a dose-dependent
manner (Figure 3B).Apigenin induced apoptotic death through the
mitochondrial apoptotic pathway in T-24 cells
We investigated whether apigenin suppresses the viabil-
ity of T-24 cells and promotes DNA fragmentation in
such cells through the activation of the mitochondrial
(intrinsic) apoptotic pathway. To determine the mito-
chondrial apoptotic events involved in apigenin-induced
apoptosis, we first analysed the changes in the levels of
Figure 3 Apigenin induced the loss of mitochondrial membrane potential and the release of cytochrome c in T-24 Cells. (A) Cultured cells
were treated with indicated concentration (0, 20, and 30 μg/ml) of apigenin for 3 and 24 h. And then, mitochondrial membrane potential was
measured by fluorescence microscope using JC-1 staining. (B) Cultured cells were treated with indicated concentration (0, 5, 10, 20, and
30 μg/ml) of apigenin for 24 h, and the expressions of cytochrome c in cytosol and mitochondria were assayed by Western blotting. The results
were represented by using an ECL system and COX-4 was the internal control. The folds were compared with control. The results were obtained from
at least three independent measurements.
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totic proteins Bcl-xL, Bcl-2, and Mcl-1. The results
showed that apigenin treatment of T-24 cells increased
the Bax, Bad, and Bak protein levels. By contrast, api-
genin decreased the Bcl-xL, Bcl-2, and Mcl-1 protein
levels (Figure 4A).
The activation of cysteine proteases, which are both initia-
tors and executors of cell death, is the hallmark of apoptosis
[28]. The results indicated that apigenin significantly acti-
vated caspase-3, caspase-7, and caspase-9 and induced
marked cleavage of PARP in T24 cells (Figure 4B).
Effects of apigenin on the expression of cell cycle-related
proteins
To identify the pathway involved in apigenin-induced
cell cycle arrest in T-24 cells, a series of experimentswere investigated in which the effects of apigenin on cell
cycle regulatory molecules. First, we measured the pro-
tein expression and phosphorylation status of p53 by
using ELISA and Western blotting. The protein expres-
sion and phosphorylation status of p53 increased signifi-
cantly in a time-dependent manner after treatment with
30 μg/ml of apigenin (Figure 5A and D). Furthermore,
the CDK inhibitors p21 and p27 were involved in cell
cycle arrest. Thus, we examined the effects of apigenin
on the p21 and p27 protein levels. The results unexpect-
edly indicated increases in the p21 and p27 protein
levels at 24 h reaching a maximum at 48 h in a time-
dependent manner (Figure 5B and C). We concluded
that apigenin-induced cell cycle arrest was associated
with an induction in the p53 protein level and p53 phos-
phoryaltion that subsequently modulated the p21 and
Figure 4 Apigenin on the protein levels of proapoptotic proteins, antiapoptotic proteins, and the activation of the caspases cascade in
T-24 cells. Cell were treated with various concentrations of apigenin for 24 h and 30 μg/ml apigenin for various periods of time (0, 1, 3, 6, and
12 h), and total cell lysates were prepared to detect (A) the protein levels of Bcl-xL, Bcl-2, Mcl-1, Bax, Bad, and Bak. (B) cleavage of caspase-3,
caspase-7, caspase-9, and PARP by Western blotting analysis. The results were represented by using an ECL system and β-actin was the internal
control. The folds were compared with control. The results were obtained from at least three independent measurements.
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fects of apigenin treatment on the Cyclin A, Cyclin B1,
Cyclin E, CDK2, Cdc2, and Cdc25C protein levels, which
are regulators of cell cycles. Our results indicated that
treatment with 30 μg/ml of apigenin reduced the Cyclin
A, Cyclin B1, Cyclin E, CDK2, Cdc2, and Cdc25C pro-
tein levels in a time-dependent manner in T24 cells
(Figure 5D).
Effects of apigenin on the intracellular levels of ROS and
GSH in T-24 cells
Several reports have suggested that ROS act upstream of
caspase-3 activation in signal transduction pathways,
and thus lead to apoptosis. Furthermore, oxidative reac-
tions in the mitochondria result in the ROS generation,
which are converted to H2O2 by superoxide dismutase.
The nonenzymatic glutathione (γ-glu-cys-gly) is the most
effective antioxidant that prevents ROS generation.
Depletion of GSH is associated with the apoptotic cell
death machinery [29]. As shown in Figure 6A, apigenin
induced an increase in intracellular ROS in a time-
dependent manner. One of the consequences of ROS
generation is scavenging of free radicals by GSH. The
intracellular levels of GSH were measured in apigenin-
treated T-24 cells at various time points. The GSH
levels were time-dependently decreased in apigenin-
treated T-24 cells (Figure 6B).
Discussion
Bladder cancer is the second most common cancer of the
genitourinary tract. Recent research has identified the food
compounds (phytochemicals) that may have crucial anti-
carcinogenic activities. Chemopreventive phytochemicalscan suppress and delay the initiation or reverse the promo-
tion stage in multistep carcinogenesis. They can block can-
cer progression by various mechanisms, including acting as
antiproliferative agents or antioxidants. Certain fruits and
vegetables possess diverse pharmacological properties and
are rich sources of phytochemicals with anticarcinogenic
potential [30,31].
Flavonoids are bioactive phytochemicals that are widely
distributed in plants and are capable of being absorbed with-
out preceding hydrolysis by the gastrointestinal tract. They
are ubiquitously found in fruits, vegetables, tea, and wine
and as plant secondary metabolites [32-34]. During the last
decade, numerous studies have shown that flavonoids and
their metabolites have various pharmacological properties.
Flavonoids have a backbone of 2-phenylchromen-4-one
(2-phenyl-1-benzopyran-4-one). Recent study has demon-
strated that apigenin could enhance anticarcinogenic ef-
fects against ultraviolet B (UVB)- and benzo(a)pyrene
(BaP)-induced skin tumour and mitochondrial dysfunc-
tion in mice. Data on skin tumorigenesis in mice have
clearly shown that pretreatment with apigenin signifi-
cantly suppresses UVB-induced skin tumour incidence
[35]. Therefore, apigenin is a glycoside form of flavonoid
which has physiological benefits when consumed in its
natural food form. Cell viability was assayed in cultures
exposed to 0–50 μM apigenin for 24 h, and apigenin ex-
hibited a dose-dependent inhibitory effect on the growth
of T-24, HT-1376, and PC-3 cells. Compared with the
other cancer cell lines, apigenin had a more effective in-
hibitory effect on the growth of T-24 (human bladder car-
cinoma cells). However, WI-38 (human nonmalignant
lung fibroblast cells) was less sensitive to the inhibitory
growth effect of apigenin than the other cancer cells,
Figure 5 (See legend on next page.)
Shi et al. Cancer Cell International  (2015) 15:33 Page 9 of 12
(See figure on previous page.)
Figure 5 The effect of apigenin on cell cycle-related molecules in T-24 cells. (A, B, C) The levels of p53, p21, and p27 in T-24 cells were
measured by ELISA kit. (D) The levels of p-p53, p53, p21, p27, Cyclin A, Cyclin B1, Cyclin E, CDK2, Cdc2, and Cdc25C were assessed by Western
blotting assay. The results represented the average of three independent experiments ± S.D. *P < 0.05, **P < 0.01 compared with the untreated
control; #P < 0.05, ##P <0.01 compared with the 0 h-treated time.
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apigenin treatment. One of the major criteria for potential
anticancer drugs is the ability to selectively kill tumour
cells but not normal cells. Furthermore, our present data
have revealed apigenin treatment resulted in a dose-
dependent accumulation of T-24 cells in the sub G1 phase
concomitantly with a reduction in the G2/M phase. No
change in S phase was observed. Our observations are
similar to those of a study on piceatannol, a natural poly-
phenol present in grapes and wine. In that study, piceatan-
nol diminished the accumulation of human T-24 and
HT1376 bladder cancer cells in the G2/M phase of the cell
cycle [36].
Further investigations are required on the association
between arrest of the G1 phase and p-p53, p53, p27, and
p21 and on the effect of apigenin on cyclins, CDKs,
Cdc2, and Cdc25C, which is associated with cyclins and
CDKs that regulate cell cycle progression in response to
apigenin treatment. Tumour suppressor gene p53 is
well-known to play a crucial role in inducing apoptosis
and cell cycle arrest after DNA damage or cellular stress
in human cells [37]. Furthermore, p53 is regarded as act-
ing as a cellular gatekeeper for growth and division by
controlling critical cell cycle checkpoints. p53 mediates
apoptosis by activating APO-1/Fas and other death re-
ceptors by upregulating and downregulating Bax and
Bcl-2, respectively. p53 is also involved in mitochondrial
generation of ROS from mitochondria, which may cause
the release of apoptotic factors. p21 and p27 proteins in-
hibit the activities of various cyclin-dependent kinases,
thereby blocking the G1 to S phase transition in the cellFigure 6 The effect of apigenin on the intracellular levels of ROS and
various periods (0, 1, 2, 3, 6, and 12 h), and then were analysed for (A) the
spectrofluorophotometer as described in “Materials and Methods” sectio
experiments ± S.D. *P < 0.05, **P < 0.01, ***P < 0.001 compared with the 0cycle [38]. Previous studies showed that p21 and p27 are
transcriptionally regulated by p53-dependent and p53-
independent pathways [39]. Our results showed that api-
genin treatment of T-24 cells results in an increase in
the p-p53, p53, p21, and p27 levels. Therefore, we sug-
gest that the blockade of cell cycle progression was
caused by the increase in the p21 and p27 protein levels,
thereby inhibiting T-24 cells proliferation. Eukaryotic
cell cycle progression involves a sequential activation of
CDKs, whose activation is dependent upon their associ-
ation with cyclins. In our study, we demonstrated that
apigenin decreased the Cyclin A, Cyclin B1, Cyclin E,
CDK2, Cdc2, and Cdc25C protein levels, whereas it in-
creased the p21, p27, p53, and p-p53 protein levels.
The mitochondrial apoptotic pathway has been con-
sidered a major signalling pathway of apoptotic cell
death in mammalian cells. The mitochondrial membrane
potential (△Ψm) often decreases in apoptosis. This de-
crease in △Ψm is mediated by the opening of permeabil-
ity transition pores [40]. In addition, electron transport
and oxidative phosphorylation are disrupted and ROS
frequently accumulate during apoptosis, suggesting a
dysfunction of mitochondria. Generated ROS include
the superoxide anion radical (.O2
−), hydroxyl radical (.OH),
hydrogen peroxide (H2O2), and peroxynitrite (ONOO
−)
[41]. The generation of ROS and the resulting oxidative
stress are implicated as cell death initiation signals that
contribute to mitochondrial dysfunction (e.g. a de-
crease in △Ψm). The nonenzymatic glutathione (c-glu-
cys-gly) is the most effective antioxidant that prevents
ROS generation. Depletion of GSH is associated withGSH in T-24 cells. Cells were treated with 30 μg/ml apigenin for
intracellular ROS production (B) the intracellular GSH content by
n. The results represented the average of three independent
h-treated time.
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in the GSH levels and concomitant increase in ROS
during apoptosis has been reported [29]. Our study
demonstrated that apigenin blocked cell cycle progres-
sion and induced late cell death in cancer cells via an
intrinsic pathway to reduce the GSH levels through the
excessive accumulation of intracellular ROS.
Furthermore, mitochondrial function is regulated by
the members of the Bcl-2 family, comprising antiapopto-
tic proteins (Bcl-2, Bcl-XL, and Mcl-1) and proapoptotic
proteins (Bax, Bad, and Bak), which control the perme-
ability of the mitochondrial membrane and play a major
role in the intrinsic apoptotic pathway [42]. After api-
genin treatment of T-24 cells, we observed a significant
increase in the expression of Bax, Bad, and Bak, and a
decrease in the expression of Bcl-2, Bcl-XL, and Mcl-1.
These findings suggest that changes in the ratio of the
proapoptotic and antiapoptotic proteins of the Bcl-2
family might contribute to the apoptosis-promoting ac-
tivity of apigenin. In addition, our results indicated that
apigenin treatment of T-24 cells reduces △Ψm and acti-
vates caspase-9, caspase-3, and caspase-7. Furthermore,
caspase-3 activation leads to cleavage of numberous
proteins, including PARP. Cleavage of PARP is a major
indicator of apoptosis. This polymerase is a nuclear
DNA-binding zinc finger protein that plays a role in
DNA repair and in other cellular processes, including
cell proliferation, differentiation, and apoptosis [43].
Consistent with this finding, apigenin-induced apop-
tosis, which involves mitochondrial apoptotic events,
was associated with the modulation of the Bcl-2 family
of proteins by apigenin. These results confirm the involve-
ment of caspases in apoptotic response to apigenin in
T-24 cells, and this involvement was confirmed by im-
munological detection of the 116 kDa intact PARP and
appearance of its 85 kDa fragment, corresponding to
the product released on caspase activation.
In summary, the present study results indicated that
(1) human bladder cancer T-24 cells are highly sensitive
to growth inhibition by apigenin; (2) apigenin can block
cell cycle progression in the subG1 phase, thereby inhi-
biting T-24 cells proliferation; (3) apigenin can inhibit
cell cycle progression involving p53 upregulation, in-
crease the expressions of p21 and p27, and reduce the
expression of Cyclin A, Cyclin B1, Cyclin E, CDK2,
Cdc2, and Cdc25C; (4) apigenin triggers the mitochon-
drial apoptotic pathway by regulating the expression of
Bcl-2 family proteins, causing the release of cytochrome
c, and activating caspase-9, caspase-7, caspase-3, and
PARP. These findings suggest that apigenin may be an
effective chemopreventive agent for bladder cancer.Competing interests
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